Preserving cognitive function in patients with Alzheimer's disease: The Alzheimer's disease neuroprotection research initiative (ADNRI)

Jie Liu; Heleen van Beusekom; Xian-Le Bu; Gong Chen; Paulo Henrique Rosado de Castro; Xiaochun Chen; Xiaowei Chen; Andrew N. Clarkson; Tracy D. Farr; Yuhong Fu; Jianping Jia; Jukka Jolkkonen; Woojin Scott Kim; Paula Korhonen; Shen Li; Yajie Liang; Guang-Hui Liu; Guiyou Liu; Yu-Hui Liu; Tarja Malm; Xiaobo Mao; Joaquim Miguel Oliveira; Mike M. Modo; Pedro Ramos-Cabrer; Karsten Ruscher; Weihong Song; Jun Wang; Xuanyue Wang; Yun Wang; Haitao Wu; Lize Xiong; Yi Yang; Keqiang Ye; Jin-Tai Yu; Xin-Fu Zhou; Marietta Zille; Colin L. Masters; Piotr Walczak; Boltze Johannes; Xunming Ji; Yan-Jiang Wang

doi:10.1002/nep3.23

Back

Preserving cognitive function in patients with Alzheimer's disease: The Alzheimer's disease neuroprotection research initiative (ADNRI)

Journal article

Open access

Peer reviewed

Preserving cognitive function in patients with Alzheimer's disease: The Alzheimer's disease neuroprotection research initiative (ADNRI)

Jie Liu, Heleen van Beusekom, Xian-Le Bu, Gong Chen, Paulo Henrique Rosado de Castro, Xiaochun Chen, Xiaowei Chen, Andrew N. Clarkson, Tracy D. Farr, Yuhong Fu, …

Neuroprotection (Chichester, England. Online), Vol.1(2), pp.84-98

12/2023

DOI: 10.1002/nep3.23

PMCID: PMC10783281

PMID: 38223913

Files and links (1)

url

https://doi.org/10.1002/nep3.23View

Published (Version of record) Open Access

Abstract

The global trend toward aging populations has resulted in an increase in the occurrence of Alzheimer's disease (AD) and associated socioeconomic burdens. Abnormal metabolism of amyloid-beta (A beta) has been proposed as a significant pathomechanism in AD, supported by results of recent clinical trials using anti-A beta antibodies. Nonetheless, the cognitive benefits of the current treatments are limited. The etiology of AD is multifactorial, encompassing A beta and tau accumulation, neuroinflammation, demyelination, vascular dysfunction, and comorbidities, which collectively lead to widespread neurodegeneration in the brain and cognitive impairment. Hence, solely removing A beta from the brain may be insufficient to combat neurodegeneration and preserve cognition. To attain effective treatment for AD, it is necessary to (1) conduct extensive research on various mechanisms that cause neurodegeneration, including advances in neuroimaging techniques for earlier detection and a more precise characterization of molecular events at scales ranging from cellular to the full system level; (2) identify neuroprotective intervention targets against different neurodegeneration mechanisms; and (3) discover novel and optimal combinations of neuroprotective intervention strategies to maintain cognitive function in AD patients. The Alzheimer's Disease Neuroprotection Research Initiative's objective is to facilitate coordinated, multidisciplinary efforts to develop systemic neuroprotective strategies to combat AD. The aim is to achieve mitigation of the full spectrum of pathological processes underlying AD, with the goal of halting or even reversing cognitive decline.

Life Sciences & Biomedicine

Neurosciences

Neurosciences & Neurology

Science & Technology

Details

Title: Subtitle: Preserving cognitive function in patients with Alzheimer's disease: The Alzheimer's disease neuroprotection research initiative (ADNRI)
Creators: Jie Liu - Army Medical University
Heleen van Beusekom - Erasmus MC
Xian-Le Bu - Third Mil Med Univ, Daping Hosp, Dept Neurol, Chongqing, Peoples R China
Gong Chen - Jinan University
Paulo Henrique Rosado de Castro - Federal Reserve
Xiaochun Chen - Fujian Medical University
Xiaowei Chen - Fujian Medical University
Andrew N. Clarkson - Brain Research New Zealand
Tracy D. Farr - University of Nottingham
Yuhong Fu - The University of Sydney
Jianping Jia - Capital Medical University
Jukka Jolkkonen - University of Eastern Finland
Woojin Scott Kim - The University of Sydney
Paula Korhonen - University of Eastern Finland
Shen Li - Capital Medical University
Yajie Liang - University of Maryland, Baltimore
Guang-Hui Liu - Univ Chinese Acad Sci, Beijing, Peoples R China
Guiyou Liu - Capital Medical University
Yu-Hui Liu - Third Mil Med Univ, Daping Hosp, Dept Neurol, Chongqing, Peoples R China
Tarja Malm - University of Eastern Finland
Xiaobo Mao - Johns Hopkins University
Joaquim Miguel Oliveira - University of Minho
Mike M. Modo - University of Pittsburgh
Pedro Ramos-Cabrer - CIC biomaGUNE
Karsten Ruscher - Lund University
Weihong Song - Wenzhou Medical University
Jun Wang - Army Medical University
Xuanyue Wang - UNSW Sydney
Yun Wang - Peking University
Haitao Wu - Beijing Institute of Education
Lize Xiong - Tongji University
Yi Yang - Jilin University
Keqiang Ye - Jilin University
Jin-Tai Yu - Fudan University
Xin-Fu Zhou - Univ South Australia, Sch Pharm & Med Sci, Div Hlth Sci, Adelaide, SA, Australia
Marietta Zille - University of Vienna
Colin L. Masters - University of Vienna
Piotr Walczak - University of Maryland, Baltimore
Boltze Johannes - University of Warwick
Xunming Ji - Capital Medical University
Yan-Jiang Wang - Third Mil Med Univ, Daping Hosp, Dept Neurol, Chongqing, Peoples R China
Resource Type: Journal article
Publication Details: Neuroprotection (Chichester, England. Online), Vol.1(2), pp.84-98
DOI: 10.1002/nep3.23
PMID: 38223913
PMCID: PMC10783281
NLM abbreviation: Neuroprotection
ISSN: 2770-7296
eISSN: 2770-730X
Publisher: Wiley
Number of pages: 15
Grant note: National Natural Science Foundation of China; National Natural Science Foundation of China (NSFC) NAF/R11/1010 / Academy of Medical Sciences; Academy of Medical Sciences (AMS) R01DA056739 / National Institutes of Health; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA
Language: English
Date published: 12/2023
Academic Unit: Radiology
Record Identifier: 9985143551802771

Metrics

1 Record Views